{"patient_id": "patient-001", "trial_id": "NCT01724606", "expert_assessments": [{"expert_name": "expert_1", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer, Brain Metastases - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_2", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer, Brain Metastases - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_3", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer, Brain Metastases - Good match for breast cancer trial", "confidence": 0.7}], "consensus_score": 4.0, "diversity_score": 0.0, "metadata": {"patient_summary": "PATIENT DEMOGRAPHICS:\n- Name: Smith Emma\n- Gender: female\n- Age: 37 years\n- ID: patient-001\n\nCONDITIONS:\n- Breast cancer\n\nKEY OBSERVATIONS:\n- No observations recorded", "trial_summary": "TRIAL INFORMATION:\n- NCT ID: NCT01724606\n- Title: Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)\n- Phase: PHASE1\n- Status: COMPLETED\n\nCONDITIONS:\n- Breast Cancer\n- Brain Metastases\nELIGIBILITY CRITERIA:\nInclusion Criteria:\n\n* Histologically-confirmed metastatic adenocarcinoma of the breast (Confirmation will be done at MSKCC)\n* Age ≥18 years.\n* Radiologic evidence of new and/or progressive brain metastasis (≥10 mm in longest dimension) by MR imaging of the Brain\n* Life expectancy of \\>12 weeks.\n* Karnofsky Performance Status (KPS) of ≥70%\n* If a patient is on corticosteroids, he/she must be on a non-escalating corticosteroid dose (not exceeding more than 16 mg daily of Dexamethasone oral) for ≥ 5 days.\n* No limit to prior therapies with last anti-cancer treatment ≥ 2 weeks from initiation of protocol based therapy provided all toxicities (other than alopecia) have resolved to ≤Grade 1 or baseline.\n* Planned WBRT based on number (≥ 3 lesions) and/or size (≥ 1 cm) of BMs (SRS) in addition to WBRT will also be eligible.\n* Patients with prior SRS will also be eligible, provided that there are new, non-irradiated measurable brain lesions.\n* No limit to prior therapies with last anti-cancer...", "assessment_timestamp": "2025-10-13T01:49:19.432Z", "framework_version": "1.0"}}
{"patient_id": "patient-001", "trial_id": "NCT04647916", "expert_assessments": [{"expert_name": "expert_1", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_2", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_3", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma - Good match for breast cancer trial", "confidence": 0.7}], "consensus_score": 4.0, "diversity_score": 0.0, "metadata": {"patient_summary": "PATIENT DEMOGRAPHICS:\n- Name: Smith Emma\n- Gender: female\n- Age: 37 years\n- ID: patient-001\n\nCONDITIONS:\n- Breast cancer\n\nKEY OBSERVATIONS:\n- No observations recorded", "trial_summary": "TRIAL INFORMATION:\n- NCT ID: NCT04647916\n- Title: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases\n- Phase: PHASE2\n- Status: ACTIVE_NOT_RECRUITING\n\nCONDITIONS:\n- Anatomic Stage IV Breast Cancer AJCC v8\n- Invasive Breast Carcinoma\n- Metastatic HER2 Negative Breast Carcinoma\n- Metastatic Malignant Neoplasm in the Brain\n- Prognostic Stage IV Breast Cancer AJCC v8\nELIGIBILITY CRITERIA:\nInclusion Criteria:\n\n* Participants must have histologically confirmed HER2-negative (per 2018 American Society of Clinical Oncology \\[ASCO\\]/College of American Pathologists \\[CAP\\] joint guideline) invasive breast cancer that has metastasized to the brain. NOTE: Pathology report must confirm HER2-negative invasive breast cancer. Brain metastases must be confirmed by radiology report\n* Participants must have an magnetic resonance imaging (MRI) of the brain within 28 days prior to registration and must have central nervous system metastases with at least one measurable brain metastasis \\>= 1.0 cm in size (per RANO-BM) that has not been irradiated, or has progressed despite prior radiation therapy (in the opinion of the treating physician). In the rare case that a previously irradiated brain metastasis is the sole target lesion and if there is concern about possible radiation necrosis, patient is eligible only if there is clear progression in the previously radiated lesion. Computed tom...", "assessment_timestamp": "2025-10-13T01:49:19.432Z", "framework_version": "1.0"}}
{"patient_id": "patient-001", "trial_id": "NCT01147016", "expert_assessments": [{"expert_name": "expert_1", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_2", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_3", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer - Good match for breast cancer trial", "confidence": 0.7}], "consensus_score": 4.0, "diversity_score": 0.0, "metadata": {"patient_summary": "PATIENT DEMOGRAPHICS:\n- Name: Smith Emma\n- Gender: female\n- Age: 37 years\n- ID: patient-001\n\nCONDITIONS:\n- Breast cancer\n\nKEY OBSERVATIONS:\n- No observations recorded", "trial_summary": "TRIAL INFORMATION:\n- NCT ID: NCT01147016\n- Title: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery\n- Phase: PHASE2\n- Status: TERMINATED\n\nCONDITIONS:\n- Breast Cancer\nELIGIBILITY CRITERIA:\nInclusion Criteria\n\n* Signed and dated institutional review board (IRB)-approved consent form\n* Women of reproductive potential must agree to use an effective nonhormonal method of contraception during therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and/or Karnofsky PS of \\>= 70%\n* Diagnosis of invasive adenocarcinoma of the breast made by core needle biopsy\n* Palpable primary breast tumor measuring \\>= 2.0 cm on physical exam or imaging prior to neoadjuvant chemotherapy\n* Patients with stage II-IIIB breast cancer that is HER2-negative by immunohistochemistry (IHC) (0-2+) and fluorescence in situ hybridization (FISH) (HER2/chromosome enumeration probe \\[CEP\\]17 amplification ratio \\< 2.0) who have completed \"third generation\" neoadjuvant chemoT and planned local treatment (surgery and radiation if indicated); estrogen receptor (ER) or progesterone receptor (PR) status should be negative\n* Patients may have lymph node positive or negative disease, a...", "assessment_timestamp": "2025-10-13T01:49:19.432Z", "framework_version": "1.0"}}
{"patient_id": "patient-002", "trial_id": "NCT01724606", "expert_assessments": [{"expert_name": "expert_1", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer, Brain Metastases - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_2", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer, Brain Metastases - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_3", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer, Brain Metastases - Good match for breast cancer trial", "confidence": 0.7}], "consensus_score": 4.0, "diversity_score": 0.0, "metadata": {"patient_summary": "PATIENT DEMOGRAPHICS:\n- Name: Johnson Olivia\n- Gender: female\n- Age: 47 years\n- ID: patient-002\n\nCONDITIONS:\n- Breast cancer\n\nKEY OBSERVATIONS:\n- No observations recorded", "trial_summary": "TRIAL INFORMATION:\n- NCT ID: NCT01724606\n- Title: Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)\n- Phase: PHASE1\n- Status: COMPLETED\n\nCONDITIONS:\n- Breast Cancer\n- Brain Metastases\nELIGIBILITY CRITERIA:\nInclusion Criteria:\n\n* Histologically-confirmed metastatic adenocarcinoma of the breast (Confirmation will be done at MSKCC)\n* Age ≥18 years.\n* Radiologic evidence of new and/or progressive brain metastasis (≥10 mm in longest dimension) by MR imaging of the Brain\n* Life expectancy of \\>12 weeks.\n* Karnofsky Performance Status (KPS) of ≥70%\n* If a patient is on corticosteroids, he/she must be on a non-escalating corticosteroid dose (not exceeding more than 16 mg daily of Dexamethasone oral) for ≥ 5 days.\n* No limit to prior therapies with last anti-cancer treatment ≥ 2 weeks from initiation of protocol based therapy provided all toxicities (other than alopecia) have resolved to ≤Grade 1 or baseline.\n* Planned WBRT based on number (≥ 3 lesions) and/or size (≥ 1 cm) of BMs (SRS) in addition to WBRT will also be eligible.\n* Patients with prior SRS will also be eligible, provided that there are new, non-irradiated measurable brain lesions.\n* No limit to prior therapies with last anti-cancer...", "assessment_timestamp": "2025-10-13T01:49:19.432Z", "framework_version": "1.0"}}
{"patient_id": "patient-002", "trial_id": "NCT04647916", "expert_assessments": [{"expert_name": "expert_1", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_2", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_3", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma - Good match for breast cancer trial", "confidence": 0.7}], "consensus_score": 4.0, "diversity_score": 0.0, "metadata": {"patient_summary": "PATIENT DEMOGRAPHICS:\n- Name: Johnson Olivia\n- Gender: female\n- Age: 47 years\n- ID: patient-002\n\nCONDITIONS:\n- Breast cancer\n\nKEY OBSERVATIONS:\n- No observations recorded", "trial_summary": "TRIAL INFORMATION:\n- NCT ID: NCT04647916\n- Title: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases\n- Phase: PHASE2\n- Status: ACTIVE_NOT_RECRUITING\n\nCONDITIONS:\n- Anatomic Stage IV Breast Cancer AJCC v8\n- Invasive Breast Carcinoma\n- Metastatic HER2 Negative Breast Carcinoma\n- Metastatic Malignant Neoplasm in the Brain\n- Prognostic Stage IV Breast Cancer AJCC v8\nELIGIBILITY CRITERIA:\nInclusion Criteria:\n\n* Participants must have histologically confirmed HER2-negative (per 2018 American Society of Clinical Oncology \\[ASCO\\]/College of American Pathologists \\[CAP\\] joint guideline) invasive breast cancer that has metastasized to the brain. NOTE: Pathology report must confirm HER2-negative invasive breast cancer. Brain metastases must be confirmed by radiology report\n* Participants must have an magnetic resonance imaging (MRI) of the brain within 28 days prior to registration and must have central nervous system metastases with at least one measurable brain metastasis \\>= 1.0 cm in size (per RANO-BM) that has not been irradiated, or has progressed despite prior radiation therapy (in the opinion of the treating physician). In the rare case that a previously irradiated brain metastasis is the sole target lesion and if there is concern about possible radiation necrosis, patient is eligible only if there is clear progression in the previously radiated lesion. Computed tom...", "assessment_timestamp": "2025-10-13T01:49:19.432Z", "framework_version": "1.0"}}
{"patient_id": "patient-002", "trial_id": "NCT01147016", "expert_assessments": [{"expert_name": "expert_1", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_2", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer - Good match for breast cancer trial", "confidence": 0.7}, {"expert_name": "expert_3", "relevance_score": 4, "justification": "Mock assessment: Patient stage Unknown, trial conditions: Breast Cancer - Good match for breast cancer trial", "confidence": 0.7}], "consensus_score": 4.0, "diversity_score": 0.0, "metadata": {"patient_summary": "PATIENT DEMOGRAPHICS:\n- Name: Johnson Olivia\n- Gender: female\n- Age: 47 years\n- ID: patient-002\n\nCONDITIONS:\n- Breast cancer\n\nKEY OBSERVATIONS:\n- No observations recorded", "trial_summary": "TRIAL INFORMATION:\n- NCT ID: NCT01147016\n- Title: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery\n- Phase: PHASE2\n- Status: TERMINATED\n\nCONDITIONS:\n- Breast Cancer\nELIGIBILITY CRITERIA:\nInclusion Criteria\n\n* Signed and dated institutional review board (IRB)-approved consent form\n* Women of reproductive potential must agree to use an effective nonhormonal method of contraception during therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and/or Karnofsky PS of \\>= 70%\n* Diagnosis of invasive adenocarcinoma of the breast made by core needle biopsy\n* Palpable primary breast tumor measuring \\>= 2.0 cm on physical exam or imaging prior to neoadjuvant chemotherapy\n* Patients with stage II-IIIB breast cancer that is HER2-negative by immunohistochemistry (IHC) (0-2+) and fluorescence in situ hybridization (FISH) (HER2/chromosome enumeration probe \\[CEP\\]17 amplification ratio \\< 2.0) who have completed \"third generation\" neoadjuvant chemoT and planned local treatment (surgery and radiation if indicated); estrogen receptor (ER) or progesterone receptor (PR) status should be negative\n* Patients may have lymph node positive or negative disease, a...", "assessment_timestamp": "2025-10-13T01:49:19.432Z", "framework_version": "1.0"}}
